Most Read Articles
Rachel Soon, 5 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Stephen Padilla, 6 days ago
Early administration of recombinant human B-type natriuretic peptide (rhBNP) can lower the incidence of reperfusion injury for patients with ST-elevation myocardial infarction (STEMI) who are receiving percutaneous coronary intervention (PCI) treatment, according to a China study.
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
3 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.

Atorvastatin a promising cardioprotective agent in rheumatoid arthritis

13 May 2019

Use of atorvastatin in patients with rheumatoid arthritis (RA) is safe and leads to substantial reductions in low-density lipoprotein (LDL) cholesterol, which translates to a 40-percent decrease in the risk of cardiovascular events, according to data from the TRACE RA trial.

TRACE-RA randomized 3,002 RA patients (mean age, 61 years; 74 percent female) to receive atorvastatin 40 mg daily or matching placebo. None of the patients had clinical atherosclerosis, diabetes or myopathy.

Over a median follow-up of 2.51 years, the primary endpoint of a composite of cardiovascular death, myocardial infarction, stroke, transient ischaemic attack or any arterial revascularization occurred in 24 patients in the atorvastatin group and in 36 patients in the placebo group (1.6 percent vs 2.4 percent, respectively; adjusted hazard ratio, 0.60; 95 percent CI, 0.32–1.15; p=0.127).

The trial was terminated prematurely due to lower than expected event rate (0.77 percent per annum).

Results for the secondary endpoint of plasma lipids favoured atorvastatin. Compared with placebo, the statin yielded greater reductions in mean LDL cholesterol (2.21 vs 2.98 mmol/L; p<0.0001) and mean C-reactive protein (2.59 vs 3.60 mg/L; p<0.0001).

Every 1-mmol/L decrease in LDL cholesterol was associated with a 42-percent reduction in the risk of cardiovascular events.

Adverse events occurred similarly in the atorvastatin and placebo groups (19.8 percent vs 19.5 percent).

The findings suggest that once-daily atorvastatin 40 mg is safe for the primary prevention of cardiovascular events in patients with RA, conferring a similar magnitude of risk reduction in these patients as in other populations, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 5 days ago

On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.

Stephen Padilla, 6 days ago
Early administration of recombinant human B-type natriuretic peptide (rhBNP) can lower the incidence of reperfusion injury for patients with ST-elevation myocardial infarction (STEMI) who are receiving percutaneous coronary intervention (PCI) treatment, according to a China study.
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
3 days ago
Pulmonary function has potential predictive value for future increases in arterial stiffness and its progression, as reported in a recent study.